LAKELAND, Dec. 20, 2025 (GLOBE NEWSWIRE) -- This educational analysis is sponsored by Health Journey, a dietary supplement company whose GLP-1 Booster product is examined as a case study within this report. While Health Journey has provided support for this research compilation, the scientific citations, industry data, and cost comparisons presented are based on publicly available information. This content is educational only, not medical advice. Readers should consult healthcare providers before starting a ...

Key Takeaways Novo Nordisk submitted an NDA for CagriSema, a once-weekly injection for long-term weight control in adults.Novo Nordisk said CagriSema delivered up to 22.7% weight loss in REDEFINE 1 and 15.7% in REDEFINE 2.NVO is diversifying beyond semaglutide as GLP-1 competition and pricing pressure weigh on recent growth.Novo Nordisk (NVO) announced the submission of a new drug application (NDA) to the FDA, seeking approval for its next-generation once-weekly injection, CagriSema, to reduce excess body w ...

Weight loss drug Mounjaro’s manufacturer, Eli Lilly and Co. (NYSE:LLY) has crossed a significant threshold in Benzinga Edge's Stock Rankings, moving into the top decile for quality this week. This improvement in fundamental strength coincides with a bullish note from Bank of America, which argues the market is still underestimating the pharmaceutical giant’s dominance in the obesity sector.Check out LLY’s price here.Entering The Top DecileIn the latest weekly data update, Eli Lilly's quality score advanced ...

Weight loss drug Mounjaro’s manufacturer, Eli Lilly and Co. (NYSE:LLY) has crossed a significant threshold in Benzinga Edge's Stock Rankings, moving into the top decile for quality this week. This improvement in fundamental strength coincides with a bullish note from Bank of America, which argues the market is still underestimating the pharmaceutical giant’s dominance in the obesity sector.Check out LLY’s price here.Entering The Top DecileIn the latest weekly data update, Eli Lilly's quality score advanced ...

市场环境与投资策略 - 投资者普遍担忧标普500指数可能在2026年出现大幅回调 主要源于对科技股泡沫和整体市场高估值的忧虑 [1] - 为应对潜在的市场动荡 可采取的投资策略包括投资于基本面良好的安全蓝筹股以降低整体风险 以及关注那些在经济下行中可能更具韧性的行业板块 [2] 艾伯维公司分析 - 在2022年标普500指数下跌超过19%的熊市中 艾伯维股价逆势上涨19% 展现出稳定性 [5] - 公司2022年营收稳步增长3% 并实现了超过20%的优秀利润率 [5] - 尽管面临其曾经最畅销药物修美乐因专利到期带来的收入替代挑战 但公司已通过免疫药物Skyrizi和Rinvoq的成功弥补了这部分损失 [6] - 公司通过创新和投资实现了持续增长 并实现了业务多元化 关键业务板块包括免疫学、肿瘤学、美学和神经科学 [6][7] - 公司股票基于分析师预估的未来收益 其市盈率为16倍 同时股息收益率为3.1% 是标普500平均股息收益率1.1%的两倍多 被视为具有价值的长期投资标的 [8] 礼来公司分析 - 在2022年市场下跌期间 礼来公司股价大幅上涨32% 显著跑赢市场 [11] - 公司的强劲增长主要得益于其非常成功的GLP-1药物 包括用于糖尿病的Mounjaro和用于减肥的Zepbound [11] 具备韧性的投资标的特征 - 值得投资的股票通常具备良好的基本面、坚实的增长前景和稳定的股息 [10] - 所提及的蓝筹股公司业务强劲 能够持续产生优异的业绩 [10] - 通过配置医疗保健和石油天然气等行业的股票 有助于实现投资组合的多元化 [10]

We came across a bullish thesis on Viking Therapeutics, Inc. on Alpha Talon Investment Research’s Substack by AT Investment Research. In this article, we will summarize the bulls’ thesis on VKTX. Viking Therapeutics, Inc.'s share was trading at $36.15 as of December 15th. Rio Tinto's CEO Announces Plan to Generate Up to $10 Billion Through Divestments & Other Strategies Copyright: dolgachov / 123RF Stock Photo Viking Therapeutics is a clinical-stage biotechnology company focused on metabolic and endocri ...

Key Points Eli Lilly has been a dominant force in the GLP-1 market, and that looks set to continue. Pfizer's acquisitions haven't paid off yet and the company is still struggling to grow its sales. The two companies are currently in very different positions -- and their valuations reflect it. 10 stocks we like better than Pfizer › Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) are two prominent names in healthcare that have focused on innovation and growing their respective businesses for decades. ...

Key Takeaways NVO is pursuing approval for Wegovy 7.2 mg to counter slowing sales amid rising GLP-1 competition.STEP UP showed Wegovy 7.2 mg delivered 20.7% average weight loss vs 17.5% with the 2.4 mg dose.NVO has filed for the approval of Wegovy 7.2 mg in the U.S. and EU, with decisions expected in 2026.Novo Nordisk (NVO) is a leading player in the obesity market, driven by its blockbuster GLP-1 therapy Wegovy (semaglutide). However, despite being a core growth driver, Wegovy’s sales momentum has slowed i ...

核心观点 - 礼来公司宣布其口服GLP-1受体激动剂orforglipron在ATTAIN-MAINTAIN三期临床试验中取得积极顶线结果，达到了主要及所有关键次要终点，证明其在52周内能有效维持先前使用Wegovy或Zepbound减掉的体重 [1] - 礼来已向美国FDA提交了orforglipron用于治疗肥胖症的新药申请 [1][5] 临床试验结果 - **主要终点**：在52周时，与安慰剂相比，orforglipron在维持体重减轻百分比方面具有优效性 [1][2] - **体重维持数据（52周）**： - 从Wegovy转为orforglipron的患者，平均仅反弹0.9公斤 [1][2] - 从Zepbound转为orforglipron的患者，平均反弹5.0公斤 [2] - **体重维持数据（24周）**： - 从Wegovy转为orforglipron的患者，体重较ATTAIN-MAINTAIN基线变化为-0.1公斤，而安慰剂组增加9.4公斤 [2] - 从Zepbound转为orforglipron的患者，体重较基线增加2.6公斤，而安慰剂组增加9.1公斤 [2] - **具体体重数据**： - Wegovy转orforglipron组：起始体重113.5公斤，转换时体重95.0公斤，52周维持治疗后体重95.9公斤 [3] - Zepbound转orforglipron组：起始体重115.8公斤，转换时体重90.9公斤，52周维持治疗后体重95.9公斤 [3] 药物安全性与试验设计 - **安全性**：orforglipron在ATTAIN-MAINTAIN试验中的安全性和耐受性特征与之前的三期研究一致，最常见不良事件为胃肠道相关，严重程度多为轻至中度 [3] - **停药率**：因不良事件导致的停药率，orforglipron组（来自Wegovy）为4.8%，安慰剂组（来自Wegovy）为7.6%；orforglipron组（来自Zepbound）为7.2%，安慰剂组（来自Zepbound）为6.3% [4] - **试验设计**：ATTAIN-MAINTAIN是一项为期52周、随机、双盲、安慰剂对照的三期试验，共纳入376名参与者，以3:2的比例随机接受orforglipron最大耐受剂量或安慰剂 [6] - **试验入组**：orforglipron的ATTAIN全球三期临床开发项目已在两项全球注册试验中招募了超过4500名肥胖或超重患者 [8] 药物背景与市场定位 - **药物特性**：orforglipron是一种每日一次口服小分子GLP-1受体激动剂，可在一天中任何时间服用，无需限制食物和水摄入 [5] - **研发进展**：礼来正在开展orforglipron用于治疗2型糖尿病和体重管理的三期研究，同时也在研究其用于治疗阻塞性睡眠呼吸暂停、高血压、膝骨关节炎等肥胖相关疾病的潜力 [5] - **监管状态**：orforglipron已获得美国FDA授予的局长国家优先审评券 [5] 相关背景：SURMOUNT-5试验 - **试验目的**：SURMOUNT-5是一项为期72周的3b期试验，旨在比较Zepbound与Wegovy在肥胖或超重成人中的疗效 [9] - **试验结果**：在72周时，Zepbound治疗组平均体重减轻20.2%，而Wegovy治疗组平均体重减轻13.7% [9] - **试验规模**：该试验在美国和波多黎各随机分配了751名参与者 [9]

Key Points These two healthcare stocks are top names to invest in, but they haven't both been doing well of late. Eli Lilly has generated $25 billion in revenue from its fast-growing GLP-1 drugs this year. Novo Nordisk, in contrast, has been facing a lot of adversity and has had to cut its guidance due to rising competition. 10 stocks we like better than Novo Nordisk › Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are two of the leading companies in the fast-growing GLP-1 weight loss market. ...